When the standard changes during the trial: Reflections on targeted therapy in FGFR2-rearranged cholangiocarcinoma.
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.